z.B. 11/24/2024
z.B. 11/24/2024

bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients

19 Juli, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has acquired ARGENE, a French company specialized in molecular diagnostics. This acquisition is bioMérieux’s tenth in the last five years.

World HAI Forum: Global Call to Action to Fight Antibiotic Resistance

30 Juni, 2011

Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics.

bioMérieux and Labor Berlin (Charité Vivantes GmbH) to Establish Center of Excellence in Laboratory Diagnostics

05 Mai, 2011

Labor Berlin and bioMérieux announce the signature of an agreement to create a Center of Excellence for microbiology and enhanced laboratory automation. The center will be located at Europe’s largest hospital laboratory, serving more than 8,000 in-house patients in Berlin and handling over 23 million patient analyses a year.

Ipsen and bioMérieux enter into a broad partnership in personalized medicine

25 Februar, 2011

The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care

bioTheranostics’ Breast Cancer IndexSM predicts risk for late recurrence in early stage ER-positive breast cancer patients

10 Dezember, 2010

bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

Pioneering diagnostics